A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...
CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of ...
Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia; Rigel Pharmaceuticals, ...
The daughter of a couple buried in a Framlingham graveyard said she was "relieved" that plans for the site had been revised.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback